Lanraplenib

Generic Name: Lanraplenib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₅N_₉O

CAS Number: 1800046-95-0

Unique Ingredient Identifier: A6U64OU57E

Background: Lanraplenib is under investigation in clinical trial NCT03285711 (Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Kronos mulls 'strategic alternatives' after axing cancer drug development

Kronos Bio discontinues istisociclib development due to safety concerns, plans strategic alternatives to maximize shareholder value, and explores partnerships for preclinical assets KB-9558 and KB-7898.

Related Clinical Trials:

A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)

A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)

openpr.com

3 months ago

Relapsed/Refractory Acute Myeloid Leukemia Clinical Trials

DelveInsight's 'Relapsed/refractory acute myeloid leukemia (AML) Pipeline Insight 2024' covers 50+ companies and 75+ pipeline drugs, including clinical and nonclinical stage products, with therapeutic assessments by product type, stage, route of administration, and molecule type. Key companies and therapies highlighted.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy